SCHEMBL5460784

SCHEMBL5460784

Nc1cc2c(cc1CO)OCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
MCL1 Q07820 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP3A4 P08684 3/20 0.39
ALOX5 P09917 1/20 0.38
CYP2D6 P10635 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
ALOX12 P18054 1/20 0.37
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27499616 0.83 MEN1 (0.42) MEN1POLBMAPTKMT2AMCL1
SCHEMBL6967405 0.80 MEN1 (0.40) MEN1POLBMAPTKMT2AMCL1
SCHEMBL2383983 0.78 CRHBP (0.43) MEN1MAPTKMT2ACYP3A4ALOX5
SCHEMBL21591954 0.78 MAPT (0.44) MEN1POLBMAPTKMT2AMCL1
SCHEMBL13754293 0.78 MAPT (0.48) MEN1POLBMAPTKMT2AMCL1
SCHEMBL546296 0.78 MAPT (0.56) MEN1POLBMAPTKMT2AMCL1
SCHEMBL29415600 0.78 MAPT (0.56) MEN1POLBMAPTKMT2AMCL1
SCHEMBL24823395 0.76 PRKCI (0.42) POLBMAPTALDH1A1
SCHEMBL24824167 0.76 PRKCI (0.42) POLBMAPT
SCHEMBL30310950 0.76 PRKCI (0.42) POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 US disclosed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 EP disclosed
US-6822097-B1 THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS AMGEN, INC. 2004-11-23 US disclosed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032518-A1 Compounds and methods of use BAX, BAD, CASP3 MEN1 1020/4885POLB 874/4885MAPT 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.